XML 55 R40.htm IDEA: XBRL DOCUMENT v3.25.0.1
Summary of Significant Accounting Policies - Additional Information (Details)
 3 Months Ended 12 Months Ended
Sep. 30, 2024
USD ($)
Jun. 30, 2024
USD ($)
Dec. 31, 2024
USD ($)
segment
shares
Dec. 31, 2023
USD ($)
shares
Jul. 29, 2022
shares
Summary of Significant Accounting Policies          
Depreciation     $ 137,000 $ 135,000  
Impairment charges of property and equipment     0 0  
In-process R&D, carrying value $ 19,800,000        
IPR&D Impairment Charges 1,300,000 $ 4,100,000 1,325,000 0  
Goodwill, at carrying value 1,500,000 5,600,000 5,600,000    
Goodwill, fair value 0 1,500,000 0    
Goodwill impairment 1,500,000 $ 4,100,000 5,594,000 0  
Impairment charge     $ 0 $ 0  
Common stock, shares issued | shares     2,811,258 715,028 2,459,016
Accrued Liabilities     $ 2,400,000 $ 1,700,000  
Prepaid Expense     $ 365,000 1,100,000  
Number of operating segments | segment     1    
Research and Development Program          
Summary of Significant Accounting Policies          
Research and development expenditure period (in months)     24 months    
In-process R&D          
Summary of Significant Accounting Policies          
In-process R&D, carrying value 19,800,000   $ 19,800,000    
In-process R&D, written down and fair value 18,600,000   18,600,000    
IPR&D Impairment Charges $ 1,300,000   $ 1,300,000    
Impairments       $ 0  
Series C and Series D Preferred Stock          
Summary of Significant Accounting Policies          
Common stock, shares issued | shares     0 98,361  
Warrant          
Summary of Significant Accounting Policies          
Antidilutive securities excluded from computation of earnings per share, amount | shares     1,428,600 0  
Options          
Summary of Significant Accounting Policies          
Antidilutive securities excluded from computation of earnings per share, amount | shares     175,034 175,049